HardyDisk AST Tebipenem 10µg (TBP10)
Hardy Diagnostics · Decision date Aug 20, 2026
What did the FDA decide?
FDA records K262113 as a 510(k) premarket notification, with a decision dated Aug 20, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Aug 20, 2026
Regulatory record facts
- Identifier
- K262113
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Hardy Diagnostics
- Product code
- JTN
- Decision code
- SESE
- Decision date
- Aug 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Susceptibility Test Discs, Antimicrobial.
- Applicant
- Hardy Diagnostics
- Product code
- JTN
- FDA device class
- 2
FDA decision timeline
K262113 received
Application receipt date recorded by FDA.
K262113 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JTN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Thermo Fisher Scientific (Oxoid Ltd.) | 510(k) clearance | Jul 24, 2026 | FDA | |
Gepotidacin GEP 10 µgK261853 | Liofilchem, Inc. | 510(k) clearance | Jul 23, 2026 | FDA |
| Hardy Diagnostics | 510(k) clearance | May 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Hardy Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Santa Maria, CA
Sources and methodology
- Original FDA record: K262113
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

